Skip to main content
Top
Published in: BMC Cancer 1/2023

Open Access 01-12-2023 | Radiotherapy | Research

Receipt of mastectomy and adjuvant radiotherapy following breast conserving surgery (BCS) in New Zealand women with BCS-eligible breast cancer, 2010–2015: an observational study focusing on ethnic differences

Authors: Karen Bartholomew, Mazin Ghafel, Sandar Tin Tin, Phyu S Aye, J Mark Elwood, Claire Hardie, Nina Scott, Jacquie Kidd, Reena Ramsaroop, Ian Campbell

Published in: BMC Cancer | Issue 1/2023

Login to get access

Abstract

Background

Women with early breast cancer who meet guideline-based criteria should be offered breast conserving surgery (BCS) with adjuvant radiotherapy as an alternative to mastectomy. New Zealand (NZ) has documented ethnic disparities in screening access and in breast cancer treatment pathways. This study aimed to determine whether, among BCS-eligible women, rates of receipt of mastectomy or radiotherapy differed by ethnicity and other factors.

Methods

The study assessed management of women with early breast cancer (ductal carcinoma in situ [DCIS] and invasive stages I-IIIA) registered between 2010 and 2015, extracted from the recently consolidated New Zealand Breast Cancer Registry (now Te Rēhita Mate Ūtaetae NZBCF National Breast Cancer Register). Specific criteria were applied to determine women eligible for BCS. Uni- and multivariable analyses were undertaken to examine differences by demographic and clinicopathological factors with a primary focus on ethnicity (Māori, Pacific, Asian, and Other; the latter is defined as NZ European, Other European, and Middle Eastern Latin American and African).

Results

Overall 22.2% of 5520 BCS-eligible women were treated with mastectomy, and 91.1% of 3807 women who undertook BCS received adjuvant radiotherapy (93.5% for invasive cancer, and 78.3% for DCIS). Asian ethnicity was associated with a higher mastectomy rate in the invasive cancer group (OR 2.18; 95%CI 1.72–2.75), compared to Other ethnicity, along with older age, symptomatic diagnosis, advanced stage, larger tumour, HER2-positive, and hormone receptor-negative groups. Pacific ethnicity was associated with a lower adjuvant radiotherapy rate, compared to Other ethnicity, in both invasive and DCIS groups, along with older age, symptomatic diagnosis, and lower grade tumour in the invasive group. Both mastectomy and adjuvant radiotherapy rates decreased over time. For those who did not receive radiotherapy, non-referral by a clinician was the most common documented reason (8%), followed by patient decline after being referred (5%).

Conclusion

Rates of radiotherapy use are high by international standards. Further research is required to understand differences by ethnicity in both rates of mastectomy and lower rates of radiotherapy after BCS for Pacific women, and the reasons for non-referral by clinicians.
Appendix
Available only for authorised users
Literature
3.
go back to reference Breast Cancer Foundation NZ. 30,000 voices: informing a better future for breast cancer in Aotearoa New Zealand. Auckland: Breast Cancer Foundation NZ; 2022. Breast Cancer Foundation NZ. 30,000 voices: informing a better future for breast cancer in Aotearoa New Zealand. Auckland: Breast Cancer Foundation NZ; 2022.
6.
go back to reference Ministry of Health NZ. Management of early breast cancer. Wellington: New Zealand Guidelines Group; 2009. Ministry of Health NZ. Management of early breast cancer. Wellington: New Zealand Guidelines Group; 2009.
11.
12.
go back to reference Haviland JS, Owen JR, Dewar JA, Agrawal RK, Barrett J, Barrett-Lee PJ, et al. The UK standardisation of breast radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials. Lancet Oncol. 2013;14:1086–94.CrossRefPubMed Haviland JS, Owen JR, Dewar JA, Agrawal RK, Barrett J, Barrett-Lee PJ, et al. The UK standardisation of breast radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials. Lancet Oncol. 2013;14:1086–94.CrossRefPubMed
13.
go back to reference Early Breast Cancer Trialists’ Collaborative Group. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10 801 women in 17 randomised trials. Lancet. 2011;378:1707–16.CrossRef Early Breast Cancer Trialists’ Collaborative Group. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10 801 women in 17 randomised trials. Lancet. 2011;378:1707–16.CrossRef
15.
go back to reference Seneviratne S, Scott N, Lawrenson R, Campbell I. Ethnic, socio-demographic and socio‐economic differences in surgical treatment of breast cancer in N ew Z ealand. ANZ J Surg. 2017;87:E32–9.CrossRefPubMed Seneviratne S, Scott N, Lawrenson R, Campbell I. Ethnic, socio-demographic and socio‐economic differences in surgical treatment of breast cancer in N ew Z ealand. ANZ J Surg. 2017;87:E32–9.CrossRefPubMed
16.
go back to reference Campbell I, Lao C, Blackmore T, Edwards M, Hayes L, Ng A, et al. Surgical treatment of early stage breast cancer in the Auckland and Waikato regions of New Zealand. ANZ J Surg. 2018;88:1263–8.CrossRefPubMed Campbell I, Lao C, Blackmore T, Edwards M, Hayes L, Ng A, et al. Surgical treatment of early stage breast cancer in the Auckland and Waikato regions of New Zealand. ANZ J Surg. 2018;88:1263–8.CrossRefPubMed
17.
go back to reference Seneviratne S, Campbell I, Scott N, Coles C, Lawrenson R. Treatment delay for Māori women with breast cancer in New Zealand. Ethn Health. 2015;20:178–93.CrossRefPubMed Seneviratne S, Campbell I, Scott N, Coles C, Lawrenson R. Treatment delay for Māori women with breast cancer in New Zealand. Ethn Health. 2015;20:178–93.CrossRefPubMed
22.
go back to reference Ministry of Health NZ. HISO 10001:2017 Ethnicity Data Protocols. Volume 10001. Wellington: Wellington: Ministry of Health; 2017. Ministry of Health NZ. HISO 10001:2017 Ethnicity Data Protocols. Volume 10001. Wellington: Wellington: Ministry of Health; 2017.
23.
go back to reference Cormack Donna, McLeod M. Improving and maintaining quality in ethnicity data collections in the health and disability sector. 2010. Cormack Donna, McLeod M. Improving and maintaining quality in ethnicity data collections in the health and disability sector. 2010.
24.
go back to reference Statistics New Zealand. Datafinder: Rurality 2020. Statistics New Zealand. Datafinder: Rurality 2020.
25.
go back to reference Atkinson J, Salmond C, Crampton P, Atkinson J, Salmond C, Crampton P. NZDep2013 index of deprivation. Wellington: Department of Public Health, University of Otago; 2014. Atkinson J, Salmond C, Crampton P, Atkinson J, Salmond C, Crampton P. NZDep2013 index of deprivation. Wellington: Department of Public Health, University of Otago; 2014.
29.
go back to reference Lao C, Lawrenson R, Edwards M, Campbell Chunhuan Lao I. Treatment and survival of asian women diagnosed with breast cancer in New Zealand. n.d. Lao C, Lawrenson R, Edwards M, Campbell Chunhuan Lao I. Treatment and survival of asian women diagnosed with breast cancer in New Zealand. n.d.
31.
go back to reference Ooi CWL, Campbell ID, Kollias J, de Silva P. National breast cancer audit: overview of invasive breast cancer in New Zealand. N Z Med J. 2012;125:8. Ooi CWL, Campbell ID, Kollias J, de Silva P. National breast cancer audit: overview of invasive breast cancer in New Zealand. N Z Med J. 2012;125:8.
34.
go back to reference Fancellu A. The need to diminish mastectomy rates in patients with breast cancer eligible for breast conservation. Updates Surg. 2019;71:597–8.CrossRefPubMed Fancellu A. The need to diminish mastectomy rates in patients with breast cancer eligible for breast conservation. Updates Surg. 2019;71:597–8.CrossRefPubMed
35.
go back to reference Health Quality & Safety Commission New Zealand. Bula Sautu : a window on quality 2021 : Pacific health in the year of COVID-19 = He mata kounga 2021 : hauora Pasifika i te tau COVID-19. n.d. Health Quality & Safety Commission New Zealand. Bula Sautu : a window on quality 2021 : Pacific health in the year of COVID-19 = He mata kounga 2021 : hauora Pasifika i te tau COVID-19. n.d.
36.
38.
go back to reference Hughes KS, Schnaper LA, Berry D, Cirrincione C, McCormick B, Shank B et al. Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast Cancer. Https://DoiOrg/101056/NEJMoa040587 2004;351:971–7. https://doi.org/10.1056/NEJMOA040587. Hughes KS, Schnaper LA, Berry D, Cirrincione C, McCormick B, Shank B et al. Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast Cancer. Https://DoiOrg/101056/NEJMoa040587 2004;351:971–7. https://​doi.​org/​10.​1056/​NEJMOA040587.
43.
go back to reference Royal Australasian College of Surgeons for Breast Surgeons of Australia and New Zealand. BreastsurgANZ Quality Audit. BreastScreen Aotearoa Annual Report 2016. Early and locally advanced breast cancer patients diagnosed in New Zealand in 2016. Melbourne: Royal Australasian College of Surgeons; 2018. Royal Australasian College of Surgeons for Breast Surgeons of Australia and New Zealand. BreastsurgANZ Quality Audit. BreastScreen Aotearoa Annual Report 2016. Early and locally advanced breast cancer patients diagnosed in New Zealand in 2016. Melbourne: Royal Australasian College of Surgeons; 2018.
49.
go back to reference Chua BH, Gray K, Krishnasamy M, Regan M, Zdenkowski N, Loi S, et al. Examining personalized radiation therapy (EXPERT): A randomised phase III trial of adjuvant radiotherapy vs observation in patients with molecularly characterized luminal A breast cancer. Cancer Res, vol. 79, AMER ASSOC CANCER RESEARCH 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA … ; 2019. Chua BH, Gray K, Krishnasamy M, Regan M, Zdenkowski N, Loi S, et al. Examining personalized radiation therapy (EXPERT): A randomised phase III trial of adjuvant radiotherapy vs observation in patients with molecularly characterized luminal A breast cancer. Cancer Res, vol. 79, AMER ASSOC CANCER RESEARCH 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA … ; 2019.
Metadata
Title
Receipt of mastectomy and adjuvant radiotherapy following breast conserving surgery (BCS) in New Zealand women with BCS-eligible breast cancer, 2010–2015: an observational study focusing on ethnic differences
Authors
Karen Bartholomew
Mazin Ghafel
Sandar Tin Tin
Phyu S Aye
J Mark Elwood
Claire Hardie
Nina Scott
Jacquie Kidd
Reena Ramsaroop
Ian Campbell
Publication date
01-12-2023
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2023
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-023-11248-9

Other articles of this Issue 1/2023

BMC Cancer 1/2023 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine